1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-07-04 am EDT
91.60 CHF   +0.22%
06/23Medacta Announces First Lumbar Fusion Procedure with NextAR Augmented Reality Surgical Platform in Australia
EQ
05/24MEDACTA : Company Presentation
PU
05/19Medacta Group announces the results of today's Annual General Meeting
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta : Company Presentation

01/17/2022 | 05:05am EDT

COMPANY PRESENTATION

An International High-Growth Platform With a New Approach to Orthopaedics

17 January 2022

DISCLAIMER

This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at https://www.medacta.com/EN/investors.

Forward-looking information

This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates", "targets", "plans", "outlook" or similar expressions.

There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this Presentation. The important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.

Alternative Performance Measures

This Presentation may contain information regarding alternative performance measures. Definitions of these measures and reconciliations between such measures and their IFRS counterparts if not defined in the Presentation may be found on the financial reports available on our website at https://www.medacta.com/EN/investors.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP

2

We are an international company specialized in the design, production and

distribution of innovative orthopaedic products and accompanying

surgical techniques for joint replacement, spine surgery and sports medicine.

| Medacta | Innovative Offering | Medical Education | Governance and Financials |

3

Innovation is the foundation of our present and future success.

Our innovation began with minimally invasive techniques and has evolved into personalized solutions for every patient.

The goal of our innovation is to improve the well-beingof our patients through innovative solutions that promote healthcare sustainability.

INNOVATION

MEDICAL EDUCATION

Transforms innovation into concrete benefits

PATIENT

HEALTHCARE

WELL-BEING

SUSTAINABILITY

| Medacta | Innovative Offering | Medical Education | Governance and Financials |

4

Proven Track Record of Growth built on the foundations of Long-Term Family Values

"Our vision resulted from my own experience: passion, innovation and medical education to create products and services that improve care and return patients to a life free from pain and disability. Our mission today is to continue to excel in all fields the Company has expanded."

Alberto Siccardi (Founder, President)

Significantly investing in new product families leveraging the existing business

SHOULDER REPLACEMENT

Continued expansion& SPORTS MED of high growth Spine

business

Established business

with strong momentumSPINE for further growth

HIP & KNEE

JOINT REPLACEMENT

Reported Revenues

Hip Knee Spine Shoulder & Sports Med

Direct Market Presence

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

|

Medacta | Innovative Offering |

Medical Education |

Governance and Financials

|

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Medacta Group SA published this content on 17 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 January 2022 10:04:08 UTC.


© Publicnow 2022
All news about MEDACTA GROUP SA
06/23Medacta Announces First Lumbar Fusion Procedure with NextAR Augmented Reality Surgical ..
EQ
05/24MEDACTA : Company Presentation
PU
05/19Medacta Group announces the results of today's Annual General Meeting
EQ
05/19Medacta Group SA Approves Distribution
CI
05/19Orthopedic Products Group Medacta Inaugurates New Offices In Switzerland
MT
05/18Medacta opens new offices in Rancate, Switzerland
EQ
05/18Medacta Group SA Opens New Offices in Rancate, Switzerland
CI
04/25Medacta's NextAR Spine Program Used in Lumbar Fusion Procedure in US
MT
04/25MEDACTA : Announces First Lumbar Fusion Procedure with NextAR Spine Augmented Reality Surg..
PU
04/25Medacta Announces First Lumbar Fusion Procedure with NextAR Spine Augmented Reality Sur..
EQ
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 418 M 436 M 436 M
Net income 2022 61,1 M 63,8 M 63,8 M
Net Debt 2022 107 M 111 M 111 M
P/E ratio 2022 29,0x
Yield 2022 0,73%
Capitalization 1 827 M 1 905 M 1 905 M
EV / Sales 2022 4,63x
EV / Sales 2023 4,04x
Nbr of Employees 1 341
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 91,37 €
Average target price 124,39 €
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-35.63%1 898
ABBOTT LABORATORIES-21.69%192 989
MEDTRONIC PLC-11.67%121 417
BECTON, DICKINSON AND COMPANY2.45%71 779
BAXTER INTERNATIONAL INC.-23.71%32 976
HOYA CORPORATION-32.14%31 045